BTX BioTime, Inc. Common Stock

3.27
-0.05  -1.51%
Previous Close 3.32
Open 3.23
Price To book 2.86
Market Cap 336.06M
Shares 102,772,000
Volume 248,319
Short Ratio 17.34
Av. Daily Volume 250,210

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six-month data due to be released by subsidiary Asterias Biotherapeutics, Inc (AST) January 24, 2017. Interim data presented September 14, 2016.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data due by mid-2017.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Data due early 2017.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
  2. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : January 12, 2017
  3. BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
  4. BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
  5. Ascendance Biotechnology Licenses the Right to Manufacture, Market and Sell Cytiva Cardiomyocytes
  6. BioTime, Inc.: Trading close to its 50 day moving average. Good buy?
  7. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : December 16, 2016
  8. BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors
  9. BioTime, Inc. – Value Analysis (NYSE MKT:BTX) : December 15, 2016
  10. ETFs with exposure to BioTime, Inc. : December 14, 2016
  11. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : December 14, 2016
  12. BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
  13. BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial
  14. BioTime to Present at Global Bioproduction Summit
  15. BioTime Co-CEO Dr. Michael D. West to Deliver Plenary Presentation on the Field of Induced Tissue Regeneration at World Stem Cell Summit
  16. ETFs with exposure to BioTime, Inc. : November 30, 2016
  17. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : November 29, 2016
  18. Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
  19. Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting
  20. BioTime, Inc.: Strong price momentum but will it sustain?

SEC Filings

  1. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17521094
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161975570
  3. 8-K - Current report 161972112
  4. 8-K - Current report 161883856
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  6. 8-K - Current report 161858352
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161819275
  8. 8-K - Current report 161818293
  9. 8-K - Current report 161751593
  10. CT ORDER - Confidential treatment order 161730665